Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Neoadjuvant vs. Adjuvant: A New Paradigm for NSCLC

Total Health

D. Carbone

ELCC 2025 Summary: Monday Morning Practice - MARIPOSA Highlights & F…

Insights from ELCC 2025

B. Halmos

Role of Surgery in Locally Advanced NSCLC

Memorial Sloan Kettering Cancer Center

K. Gray

EGFRm Lung Cancer: Overview & Treatment Sequence

GRACE

J. Rotow

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-…

ecancer

L. Paz-Ares

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

IO Advances in Metastatic NSCLC Treatment

Fox Chase Cancer Center

H. Borghaei

Imaging of Precision Therapy in Lung Cancer

International Cancer Imaging Society (ICIS)

M. Nishino

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Current Landscape of Neoadjuvant, Perioperative, and Adjuvant IO in …

UCLA Health

J. Lee

Evolution of 1L EGFR TKI Therapy in mNSCLC

Fawzi Abu Rous

Year in Review 2024 - Targeted Therapy for NSCLC

Nebraska Oncology Society

J. Murray

Reading a Molecular Testing Report in Lung Cancer

GRACE

K. Yun

WCLC 2024 Review: MARIPOSA Trial - Extended Follow Up and Patient Re…

ecancer

E. Felip

Managing Cutaneous Toxicities in EGFRm NSCLC: Insights From Amivanta…

Catherine Shu

EGFR and HER2 Targeted Therapies in NSCLC: New Developments and a Ch…

GRACE

X. Le

The Future of Lung Cancer Treatment: What’s on the Horizon?

GRACE

J. Rotow, I. Dagogo-Jack, M. Shields, A. Cooper, A. Qin

Biomarker Testing in aNSCLC: Current Guidelines, Gaps, and Impact on…

UChicago Medicine

R. Thawani